E
Harrow, Inc.
HROW
$23.52
-$0.54-2.24%
E
Sell
3/28/2025Downgrade
Harrow, Inc. (HROW) was downgraded to E+ from D- on 3/28/2025 due to a significant decline in the total return index and volatility index.
Harrow, Inc. (HROW) was downgraded to E+ from D- on 3/28/2025 due to a significant decline in the total return index and volatility index.
D
Sell
11/4/2024Upgraded
Harrow, Inc. (HROW) was upgraded to D- from E+ on 11/4/2024 due to an increase in the total return index and volatility index.
Harrow, Inc. (HROW) was upgraded to D- from E+ on 11/4/2024 due to an increase in the total return index and volatility index.
E
Sell
9/25/2024Downgrade
Harrow, Inc. (HROW) was downgraded to E+ from D- on 9/25/2024 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.57 to 2.33, and debt to equity increased from 3.05 to 3.17.
Harrow, Inc. (HROW) was downgraded to E+ from D- on 9/25/2024 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 2.57 to 2.33, and debt to equity increased from 3.05 to 3.17.
D
Sell
3/14/2023Downgrade
Harrow Health, Inc. (HROW) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
Harrow Health, Inc. (HROW) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/23/2023Upgraded
Harrow Health, Inc. (HROW) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Harrow Health, Inc. (HROW) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Harrow Health, Inc. (HROW) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
Harrow Health, Inc. (HROW) was downgraded to D- from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
11/18/2022Downgrade
Harrow Health, Inc. (HROW) was downgraded to D from D+ on 11/18/2022 due to a noticeable decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 12.64 to 59.94, the quick ratio declined from 4.53 to 3.05, and total capital declined 5.19% from $85.77M to $81.32M.
Harrow Health, Inc. (HROW) was downgraded to D from D+ on 11/18/2022 due to a noticeable decline in the efficiency index, solvency index and valuation index. Debt to equity increased from 12.64 to 59.94, the quick ratio declined from 4.53 to 3.05, and total capital declined 5.19% from $85.77M to $81.32M.
D
Sell
10/31/2022Upgraded
Harrow Health, Inc. (HROW) was upgraded to D+ from D on 10/31/2022 due to a substantial increase in the total return index, efficiency index and volatility index.
Harrow Health, Inc. (HROW) was upgraded to D+ from D on 10/31/2022 due to a substantial increase in the total return index, efficiency index and volatility index.
D
Sell
5/5/2022Upgraded
Harrow Health, Inc. (HROW) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
Harrow Health, Inc. (HROW) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index.
D
Sell
4/20/2022Downgrade
Harrow Health, Inc. (HROW) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 4.33 to 6.37, and the quick ratio declined from 6.86 to 5.69.
Harrow Health, Inc. (HROW) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index, solvency index and volatility index. Debt to equity increased from 4.33 to 6.37, and the quick ratio declined from 6.86 to 5.69.
D
Sell
11/11/2021Downgrade
Harrow Health, Inc. (HROW) was downgraded to D from C on 11/11/2021 due to a significant decline in the efficiency index, valuation index and solvency index. Net income declined 236.08% from -$2.48M to -$8.33M, debt to equity increased from 3.09 to 4.33, and the quick ratio declined from 10.88 to 6.86.
Harrow Health, Inc. (HROW) was downgraded to D from C on 11/11/2021 due to a significant decline in the efficiency index, valuation index and solvency index. Net income declined 236.08% from -$2.48M to -$8.33M, debt to equity increased from 3.09 to 4.33, and the quick ratio declined from 10.88 to 6.86.
C
Hold
11/3/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to C from C- on 11/3/2021 due to a large increase in the total return index and volatility index.
Harrow Health, Inc. (HROW) was upgraded to C from C- on 11/3/2021 due to a large increase in the total return index and volatility index.
C
Hold
8/12/2021Downgrade
Harrow Health, Inc. (HROW) was downgraded to C- from C+ on 8/12/2021 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $0.0083 to -$0.1103.
Harrow Health, Inc. (HROW) was downgraded to C- from C+ on 8/12/2021 due to a significant decline in the growth index, valuation index and total return index. Earnings per share declined from $0.0083 to -$0.1103.
C
Hold
8/2/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to C+ from C on 8/2/2021 due to an increase in the total return index and valuation index.
Harrow Health, Inc. (HROW) was upgraded to C+ from C on 8/2/2021 due to an increase in the total return index and valuation index.
C
Hold
7/7/2021Downgrade
Harrow Health, Inc. (HROW) was downgraded to C from C+ on 7/7/2021 due to a noticeable decline in the total return index and valuation index.
Harrow Health, Inc. (HROW) was downgraded to C from C+ on 7/7/2021 due to a noticeable decline in the total return index and valuation index.
C
Hold
6/21/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to C+ from C on 6/21/2021 due to a noticeable increase in the total return index and valuation index.
Harrow Health, Inc. (HROW) was upgraded to C+ from C on 6/21/2021 due to a noticeable increase in the total return index and valuation index.
C
Hold
6/2/2021Downgrade
Harrow Health, Inc. (HROW) was downgraded to C from C+ on 6/2/2021 due to a large decline in the total return index, valuation index and volatility index.
Harrow Health, Inc. (HROW) was downgraded to C from C+ on 6/2/2021 due to a large decline in the total return index, valuation index and volatility index.
C
Hold
5/13/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to C+ from C on 5/13/2021 due to a major increase in the total return index.
Harrow Health, Inc. (HROW) was upgraded to C+ from C on 5/13/2021 due to a major increase in the total return index.
C
Hold
5/12/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to C from C- on 5/12/2021 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 666.78% from -$566 to $3.21M, debt to equity declined from 0.62 to 0.51, and EBIT increased 11.08% from $2.63M to $2.92M.
Harrow Health, Inc. (HROW) was upgraded to C from C- on 5/12/2021 due to a significant increase in the growth index, valuation index and solvency index. Operating cash flow increased 666.78% from -$566 to $3.21M, debt to equity declined from 0.62 to 0.51, and EBIT increased 11.08% from $2.63M to $2.92M.
C
Hold
4/29/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to C- from D+ on 4/29/2021 due to a substantial increase in the total return index, efficiency index and volatility index. Total capital increased 2.31% from $49.22M to $50.36M.
Harrow Health, Inc. (HROW) was upgraded to C- from D+ on 4/29/2021 due to a substantial increase in the total return index, efficiency index and volatility index. Total capital increased 2.31% from $49.22M to $50.36M.
D
Sell
1/29/2021Upgraded
Harrow Health, Inc. (HROW) was upgraded to D+ from D on 1/29/2021 due to an increase in the total return index and volatility index.
Harrow Health, Inc. (HROW) was upgraded to D+ from D on 1/29/2021 due to an increase in the total return index and volatility index.
D
Sell
12/4/2020Downgrade
Harrow Health, Inc. (HROW) was downgraded to D from D+ on 12/4/2020 due to a decline in the total return index.
Harrow Health, Inc. (HROW) was downgraded to D from D+ on 12/4/2020 due to a decline in the total return index.
D
Sell
11/19/2020Upgraded
Harrow Health, Inc. (HROW) was upgraded to D+ from D on 11/19/2020 due to a major increase in the efficiency index, total return index and solvency index. Net income increased 3,744.73% from -$237 to $8.64M, debt to equity declined from 1.16 to 0.69, and the quick ratio increased from 1.98 to 2.63.
Harrow Health, Inc. (HROW) was upgraded to D+ from D on 11/19/2020 due to a major increase in the efficiency index, total return index and solvency index. Net income increased 3,744.73% from -$237 to $8.64M, debt to equity declined from 1.16 to 0.69, and the quick ratio increased from 1.98 to 2.63.
D
Sell
8/11/2020Upgraded
Harrow Health, Inc. (HROW) was upgraded to D from D- on 8/11/2020 due to an increase in the total return index, efficiency index and volatility index. Net income increased 98.16% from -$12.91M to -$237, and total capital increased 9.97% from $36.06M to $39.65M.
Harrow Health, Inc. (HROW) was upgraded to D from D- on 8/11/2020 due to an increase in the total return index, efficiency index and volatility index. Net income increased 98.16% from -$12.91M to -$237, and total capital increased 9.97% from $36.06M to $39.65M.
D
Sell
5/12/2020Downgrade
Harrow Health, Inc. (HROW) was downgraded to D- from D on 5/12/2020 due to a large decline in the efficiency index, total return index and solvency index. Net income declined 585.77% from $2.66M to -$12.91M, debt to equity increased from 0.53 to 0.96, and the quick ratio declined from 2.67 to 1.55.
Harrow Health, Inc. (HROW) was downgraded to D- from D on 5/12/2020 due to a large decline in the efficiency index, total return index and solvency index. Net income declined 585.77% from $2.66M to -$12.91M, debt to equity increased from 0.53 to 0.96, and the quick ratio declined from 2.67 to 1.55.
D
Sell
3/16/2020Downgrade
Harrow Health, Inc. (HROW) was downgraded to D from C on 3/16/2020 due to a significant decline in the valuation index, growth index and total return index. Total revenue declined 1.18% from $12.76M to $12.6M.
Harrow Health, Inc. (HROW) was downgraded to D from C on 3/16/2020 due to a significant decline in the valuation index, growth index and total return index. Total revenue declined 1.18% from $12.76M to $12.6M.
C
Hold
7/11/2019Upgraded
Harrow Health, Inc. (HROW) was upgraded to C from C- on 7/11/2019 due to an increase in the total return index.
Harrow Health, Inc. (HROW) was upgraded to C from C- on 7/11/2019 due to an increase in the total return index.
C
Hold
5/15/2019Downgrade
Harrow Health, Inc. (HROW) was downgraded to C- from C on 5/15/2019 due to a decline in the growth index, efficiency index and volatility index. Operating cash flow declined 4,000% from -$36 to -$1.48M, net income declined 37.35% from $18.13M to $11.36M, and earnings per share declined from $0.5742 to $0.43.
Harrow Health, Inc. (HROW) was downgraded to C- from C on 5/15/2019 due to a decline in the growth index, efficiency index and volatility index. Operating cash flow declined 4,000% from -$36 to -$1.48M, net income declined 37.35% from $18.13M to $11.36M, and earnings per share declined from $0.5742 to $0.43.
C
Hold
5/1/2019Upgraded
Harrow Health, Inc. (HROW) was upgraded to C from C- on 5/1/2019 due to an increase in the total return index.
Harrow Health, Inc. (HROW) was upgraded to C from C- on 5/1/2019 due to an increase in the total return index.
C
Hold
4/16/2019Upgraded
Harrow Health, Inc. (HROW) was upgraded to C- from D- on 4/16/2019 due to a significant increase in the valuation index, solvency index and total return index. The quick ratio increased from 0.77 to 2.53, and debt to equity declined from 3.43 to 0.62.
Harrow Health, Inc. (HROW) was upgraded to C- from D- on 4/16/2019 due to a significant increase in the valuation index, solvency index and total return index. The quick ratio increased from 0.77 to 2.53, and debt to equity declined from 3.43 to 0.62.
D
Sell
6/11/2018Upgraded
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 6/11/2018 due to an increase in the total return index, volatility index and growth index.
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 6/11/2018 due to an increase in the total return index, volatility index and growth index.
E
Sell
5/16/2018Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 5/16/2018 due to a substantial decline in the solvency index, growth index and valuation index. Debt to equity increased from 5.61 to 177.98, operating cash flow declined 228.23% from -$294 to -$965, and earnings per share declined from -$0.1339 to -$0.17.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 5/16/2018 due to a substantial decline in the solvency index, growth index and valuation index. Debt to equity increased from 5.61 to 177.98, operating cash flow declined 228.23% from -$294 to -$965, and earnings per share declined from -$0.1339 to -$0.17.
D
Sell
5/10/2018Upgraded
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 5/10/2018 due to an increase in the total return index and volatility index.
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 5/10/2018 due to an increase in the total return index and volatility index.
E
Sell
3/12/2018Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 3/12/2018 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 3.9 to 5.61, the quick ratio declined from 1.1 to 0.96, and total capital declined 6.41% from $19.23M to $17.99M.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 3/12/2018 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 3.9 to 5.61, the quick ratio declined from 1.1 to 0.96, and total capital declined 6.41% from $19.23M to $17.99M.
D
Sell
2/23/2018Upgraded
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 2/23/2018 due to an increase in the total return index and volatility index.
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 2/23/2018 due to an increase in the total return index and volatility index.
E
Sell
2/8/2018Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 2/8/2018 due to a decline in the volatility index.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 2/8/2018 due to a decline in the volatility index.
D
Sell
1/3/2018Upgraded
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 1/3/2018 due to an increase in the total return index and volatility index.
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 1/3/2018 due to an increase in the total return index and volatility index.
E
Sell
12/19/2017Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 12/19/2017 due to a noticeable decline in the solvency index, total return index and valuation index. Debt to equity increased from 1.64 to 3.9, and the quick ratio declined from 1.31 to 1.1.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 12/19/2017 due to a noticeable decline in the solvency index, total return index and valuation index. Debt to equity increased from 1.64 to 3.9, and the quick ratio declined from 1.31 to 1.1.
D
Sell
3/22/2017Upgraded
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 3/22/2017 due to an increase in the solvency index, valuation index and efficiency index. Debt to equity declined from 3.7 to 1.96, total capital increased 38.21% from $14.74M to $20.38M, and the quick ratio increased from 0.96 to 1.2.
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to D- from E+ on 3/22/2017 due to an increase in the solvency index, valuation index and efficiency index. Debt to equity declined from 3.7 to 1.96, total capital increased 38.21% from $14.74M to $20.38M, and the quick ratio increased from 0.96 to 1.2.
E
Sell
12/9/2016Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 12/9/2016 due to a decline in the total return index and volatility index.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to E+ from D- on 12/9/2016 due to a decline in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, solvency index and total return index. Debt to equity increased from 1.65 to 3.9, and the quick ratio declined from 4.03 to 1.96.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, solvency index and total return index. Debt to equity increased from 1.65 to 3.9, and the quick ratio declined from 4.03 to 1.96.
D
Sell
8/15/2014Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D from D+ on 8/15/2014 due to a decline in the efficiency index, valuation index and total return index. Total capital declined 12.58% from $13.8M to $12.06M.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D from D+ on 8/15/2014 due to a decline in the efficiency index, valuation index and total return index. Total capital declined 12.58% from $13.8M to $12.06M.
D
Sell
5/16/2014Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D+ from C- on 5/16/2014 due to a decline in the growth index, total return index and solvency index. Total revenue declined 44% from $2.5 to $1.4, and the quick ratio declined from 23.95 to 21.73.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D+ from C- on 5/16/2014 due to a decline in the growth index, total return index and solvency index. Total revenue declined 44% from $2.5 to $1.4, and the quick ratio declined from 23.95 to 21.73.
C
Hold
4/14/2014Upgraded
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to C- from D+ on 4/14/2014 due to a noticeable increase in the total return index, valuation index and volatility index.
Imprimis Pharmaceuticals, Inc. (IMMY) was upgraded to C- from D+ on 4/14/2014 due to a noticeable increase in the total return index, valuation index and volatility index.
D
Sell
3/28/2014Downgrade
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D+ from C- on 3/28/2014 due to a major decline in the efficiency index, valuation index and solvency index. Net income declined 9.41% from -$2.08M to -$1.88M, and total capital declined 7.55% from $16.34M to $15.11M.
Imprimis Pharmaceuticals, Inc. (IMMY) was downgraded to D+ from C- on 3/28/2014 due to a major decline in the efficiency index, valuation index and solvency index. Net income declined 9.41% from -$2.08M to -$1.88M, and total capital declined 7.55% from $16.34M to $15.11M.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
